Author: Dr Neil Fawkes, MBChB, DPM, FFPM - Chief Medical Officer, AmiLyfe Bioscience, LLC
Published: 3/6/2026 | Last Reviewed: 3/5/2026
Quick Answer
Dehydration is one of the most common and preventable complications of cancer treatment, affecting patients across chemotherapy, radiation, and immunotherapy regimens. When gastrointestinal (GI) symptoms such as diarrhea and vomiting occur, fluid and electrolyte loss can escalate quickly, increasing the risk of treatment delays and unplanned hospitalizations. Cancer therapy can damage the intestinal lining and impair SGLT1-mediated glucose sodium transport, a key pathway involved in fluid absorption. When this pathway is disrupted, sugary drinks may not be absorbed efficiently and can draw additional water into the gut. Effective hydration requires replacement of electrolytes through transport systems that remain functional despite intestinal injury. Glucose-free, amino acid-based medical foods such as enterade® use sodium amino acid co-transport and have been evaluated in clinical studies demonstrating reductions in diarrhea severity and the need for intravenous hydration when used under medical supervision.
Introduction: Hydration Is Not Optional During Cancer Treatment
Most patients entering cancer treatment understand that staying hydrated is important. What is less widely appreciated is how significantly cancer therapy can alter the body's ability to absorb and regulate fluids, and why that distinction matters when planning a hydration strategy during treatment.
Under normal circumstances, the intestinal lining efficiently absorbs water and electrolytes from what we drink and eat. During chemotherapy, radiation, and certain targeted or immunotherapy regimens, that lining is often injured. When this occurs, the intestine’s absorptive capacity can be impaired. Fluid that would normally be taken up by the intestine can instead remain in the gut, contributing to diarrhea and accelerating both fluid and electrolyte losses. In this setting, simply drinking more water may not be enough to maintain adequate hydration.
This article explains why dehydration can develop during cancer treatment, why electrolytes are essential for effective intestinal fluid absorption, where common hydration strategies may fall short, and how to build a more effective, physiologically appropriate hydration strategy that supports the body throughout therapy.
Why Cancer Treatment Increases Dehydration Risk
Dehydration during cancer treatment rarely has a single cause. In most cases, it results from multiple overlapping factors acting simultaneously and reinforcing one another.
Many chemotherapy treatments damage rapidly dividing cells lining the gastrointestinal (GI) tract, reducing the intestine's ability to absorb fluids and electrolytes effectively. At the same time, nausea and vomiting decrease oral intake, while diarrhea accelerates ongoing fluid and electrolyte loss. Some patients experience a reduced thirst sensation, allowing dehydration to progress before they feel the need to drink. Medications commonly used during treatment, including certain antiemetics and pain relievers, can further disrupt gut motility and fluid balance.
Radiation therapy directly damages intestinal lining cells, leading to inflammation, impaired absorption, and diarrhea. In some cases, these effects may persist for weeks or months after treatment concludes.
Targeted therapies and immune checkpoint inhibitors introduce additional hydration risks. EGFR inhibitors are frequently associated with diarrhea, and immune-mediated colitis, a known complication of checkpoint inhibitor therapy, can produce rapid and substantial fluid loss. Together, reduced intake, impaired intestinal absorption, and increased gastrointestinal losses combine to create a high risk of dehydration during treatment.
What Electrolytes Do and Why They Are Lost During Treatment
Electrolytes are minerals that carry an electrical charge when dissolved in fluid. Sodium, potassium, magnesium, phosphorus, and chloride are among the most clinically important. They regulate fluid balance between cells and the bloodstream, support nerve and muscle function, maintain heart rhythm, and play a critical role in driving intestinal fluid absorption.
In healthy individuals, electrolyte levels are tightly regulated by the coordinated actions of the kidneys, intestines, and hormonal systems. During cancer treatment, this balance can be disrupted through several mechanisms. Diarrhea and vomiting rapidly deplete sodium, potassium, and magnesium. Certain chemotherapy agents, particularly platinum-based drugs such as cisplatin, can damage kidney tubules, impairing the body’s ability to retain magnesium and other electrolytes. Reduced food intake further limits the ability to replace dietary electrolytes.
The consequences of electrolyte imbalance extend well beyond thirst or fatigue. Hyponatremia (low sodium) can cause confusion, headache, and in severe cases, seizures. Hypokalemia (low potassium) can impair cardiac and muscle function. Hypomagnesemia (low magnesium) is associated with muscle cramping, weakness, and potentially dangerous cardiac arrhythmias. These well-recognized complications in oncology patients require careful monitoring and proactive management.
Why Water Alone Is Often Not Enough
The relationship between fluid intake and hydration status is more complex during cancer treatment than under normal conditions.
Water absorption in the intestine is largely driven by osmotic gradients created by sodium and other solute transport pathways. When the intestinal lining is healthy, sodium transporters move sodium into the intestinal cells, and water follows osmotically into the bloodstream. When chemotherapy or radiation damages the intestinal lining, these absorptive transport pathways can become less efficient. As a result, water consumed without adequate electrolytes may not be absorbed efficiently. In patients with active diarrhea, unabsorbed fluid can remain in the gut, increasing intestinal water content and potentially worsening stool output.
This helps explain why drinking large volumes of plain water during active diarrhea does not always resolve dehydration. When the gut's absorptive capacity is compromised, the composition of what is consumed becomes just as important as the total volume of fluid intake.
Limitations of Common Hydration Drinks During Cancer Treatment
When gastrointestinal (GI) symptoms begin, patients and caregivers often reach for familiar beverage options, including commercial sports drinks, fruit juices, sodas, or electrolyte powders marketed for general wellness. While these products may be appropriate for athletes or mild dehydration from exercise, they are not designed for the physiological demands of cancer treatment-related GI dysfunction.
Many standard sports drinks rely on glucose-coupled sodium transport to facilitate fluid absorption. In a healthy intestine, glucose-coupled sodium transport is effective. However, when treatment-related injury affects the intestinal lining and active diarrhea is present, higher glucose concentrations can increase osmotic pressure in the gut lumen, drawing additional water into the lumen and potentially worsening diarrhea in some patients. High-sugar beverages may also be poorly tolerated during periods of nausea.
Fruit juices, sodas, and sweetened beverages raise similar concerns. They often contain high concentrations of fructose or sucrose with relatively little sodium, limiting their effectiveness as hydration tools during active GI episodes. In addition, when the mucosal lining is damaged, glucose-dependent transport pathways may be less efficient, further reducing absorption efficiency and contributing to ongoing fluid loss (diarrhea).
The clinical needs of oncology patients during treatment-related GI distress are specific: effective delivery of fluids and electrolytes through absorptive pathways that remain functional despite mucosal injury, while minimizing excess sugar and osmotic load.
A Hydration Strategy Built for Cancer Treatment
Effective hydration during cancer treatment requires a structured, consistent approach rather than reactive drinking when thirst develops. The following strategies reflect principles of supportive care commonly used in oncology practice.
Drink consistently throughout the day. Waiting until thirst develops is not a reliable hydration strategy during treatment, particularly for patients experiencing nausea or reduced appetite. Establishing regular fluid intake targets, such as planned volumes by mid-morning, mid-afternoon, and evening, helps maintain more stable hydration and electrolyte balance.
Increase fluid intake proactively during GI episodes. When diarrhea or vomiting begins, fluid and electrolyte losses accelerate. Prompt replacement, rather than waiting for symptoms to resolve, reduces the risk of clinically significant dehydration.
Prioritize electrolyte replacement alongside fluids. Water alone is insufficient during periods of active GI fluid loss. Patients should discuss appropriate electrolyte replacement strategies with their oncology team, especially during frequent diarrhea or vomiting.
Use oncology-appropriate hydration products. Not all hydration products are suitable for treatment-related GI symptoms. enterade® is a sugar-free, amino acid-based medical food formulated for the dietary management of gastrointestinal dysfunction associated with cancer therapy. Its formulation uses amino acid–coupled sodium transport pathways to support fluid absorption during periods of intestinal stress. Clinical studies in oncology populations have demonstrated reductions in the severity of diarrhea and a decreased need for intravenous hydration when used under medical supervision. enterade® is available without a prescription through major retailers, including Amazon.
Monitor for signs of dehydration daily. Urine color is a practical and reliable indicator of hydration status. Pale yellow urine generally indicates adequate hydration, while dark yellow or amber urine, reduced output, dizziness, dry mouth, rapid heartbeat, or confusion may signal developing dehydration and warrant prompt contact with the oncology team.
Communicate changes in fluid tolerance to your care team. If maintaining oral fluid intake becomes difficult due to nausea, vomiting, or severe diarrhea, the oncology team should be notified promptly. Intravenous hydration may be necessary, and early intervention reduces the risk of treatment delays and hospitalization.
The Link Between Hydration and Treatment Tolerability
Maintaining adequate hydration during cancer treatment is not only about preventing dehydration. It directly influences how well a patient tolerates therapy and whether treatment can proceed as scheduled.
Hydration plays a critical role in kidney function, which is essential for clearing many chemotherapy agents from the body. Several commonly used treatments are nephrotoxic, and adequate fluid status helps reduce the risk of treatment-related kidney injury during and following infusion. When patients arrive for therapy with signs of dehydration, chemotherapy may be postponed until hydration is restored, potentially disrupting the planned treatment schedule.
Hydration also affects energy levels, cognitive clarity, and appetite. Even mild chronic dehydration can worsen fatigue, impair concentration, and intensify nausea, further reducing oral intake and creating a cycle of declining hydration and nutrition that can be difficult to reverse without intervention.
Supportive oncology research has demonstrated that proactive hydration strategies are associated with improved treatment tolerance, fewer unplanned clinic visits, and lower rates of hospitalization for dehydration-related complications.
When to Seek Medical Attention for Dehydration
Mild dehydration can often be managed at home with consistent oral fluid and electrolyte intake. However, certain signs suggest that dehydration may be progressing and should prompt medical evaluation.
Contact your oncology team promptly if you experience any of the following:
- Inability to keep fluids down for more than 12 hours due to persistent vomiting
- Diarrhea exceeding six episodes within a 24-hour period
- Dark urine or significantly reduced urine output over several hours
- Dizziness, lightheadedness, or fainting, particularly when standing
- Rapid heartbeat while at rest
- Confusion or new difficulty concentrating
- Fever above 100.4°F (38°C) accompanied by gastrointestinal symptoms
- Significant unintended weight loss over a short period
These symptoms may indicate clinically meaningful dehydration or electrolyte imbalance that requires timely medical management. Severe or persistent symptoms should not be managed at home without guidance from the oncology care team.
The Role of the Oncology Care Team in Hydration Management
Hydration management during cancer treatment should be guided by the oncology care team. Oncology nurses, physicians, and registered dietitians each play a critical role in monitoring fluid status, identifying early signs of dehydration, and recommending timely interventions.
At many cancer centers, patients receive intravenous pre-hydration before certain chemotherapy infusions, particularly with nephrotoxic regimens such as platinum-based therapies, to help protect kidney function and maintain electrolyte balance. Post-infusion hydration protocols are also commonly used. Between appointments, the oncology nursing team is often the first point of contact for patients experiencing gastrointestinal symptoms that interfere with fluid intake.
Oncology registered dietitians provide individualized guidance on hydration strategies, appropriate beverage choices, and maintaining adequate calorie and fluid intake when GI symptoms make eating and drinking difficult. For patients without direct access to an oncology dietitian, telehealth-based nutrition services may offer practical, accessible support.
Key Takeaways
Hydration during cancer treatment is a clinical priority that requires a more targeted approach than hydration under normal conditions. Treatment-related gastrointestinal symptoms, such as diarrhea and vomiting, rapidly deplete fluids and electrolytes, and therapy-induced intestinal injury can impair the gut’s ability to absorb nutrients. During periods of active GI distress, water alone may be insufficient to maintain adequate hydration. Effective hydration means replacing electrolytes alongside fluids, selecting hydration strategies appropriate for oncology care, monitoring daily for early signs of dehydration, and communicating changes in fluid tolerance promptly to the care team.
Medical foods such as enterade®, developed for the dietary management of gastrointestinal dysfunction associated with cancer therapy, are designed to support fluid and electrolyte absorption during periods of intestinal stress without adding excess glucose. Proper hydration throughout treatment is not a secondary concern; it is a foundational component of comprehensive supportive oncology care.
Sources and References
1. Arends, Jann et al. “ESPEN guidelines on nutrition in cancer patients.” Clinical nutrition (Edinburgh, Scotland) vol. 36,1 (2017): 11-48. https://doi.org/10.1016/j.clnu.2016.07.015
2. Chauhan, A., Das, S., Miller, R., Luque, L., Cheuvront, S. N., Cloud, J., Anthony, L. (2021). Can an amino acid mixture alleviate gastrointestinal symptoms in neuroendocrine tumor patients? BMC Cancer, 21(1), 580. https://doi.org/10.1186/s12885-021-08315-4
3. De Filipp, Z., Glotzbecker, B., Luque, L., Kim, H. T., Mitchell, K. M., Cheuvront, S. N., & Soiffer, R. J. (2021). Randomized study of enterade® to reduce diarrhea in patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation. Asian Pacific Journal of Cancer Prevention, 22(1), 301–304. https://doi.org/10.31557/APJCP.2021.22.1.301
4. Gupta, R., Yin, L., Grosche, A., Lin, S., Xu, X., Guo, J., Vaught, L. A., Okunieff, P. G., & Vidyasagar, S. (2020). An amino acid–based oral rehydration solution regulates radiation-induced intestinal barrier disruption in mice. The Journal of Nutrition, 150(5), 1100–1108. https://doi.org/10.1093/jn/nxaa025
5. Hendrie, J. D., Chauhan, A., Nelson, N. R., & Anthony, L. B. (2019). Can an amino acid-based oral rehydration solution be effective in managing immune therapy-induced diarrhea? Medical Hypotheses, 127, 66–70. https://doi.org/10.1016/j.mehy.2019.03.023
6. Hesketh, Paul J et al. “Antiemetics: ASCO Guideline Update.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 38,24 (2020): 2782-2797. https://doi.org/10.1200/JCO.20.01296
7. Luque, L., Cheuvront, S. N., Mantz, C., & Finkelstein, S. E. (2020). Alleviation of cancer therapy-induced gastrointestinal toxicity using an amino acid medical food. Food & Nutrition Journal, 5, 216. https://doi.org/10.29011/2575-7091.100116
8. Mitchell, L. F., Ansman, H., Jackie, A., Carver, J. E., Clark, P. R., & Cronin, S. N. (2023). JL1115C: Evaluating the use of an amino acid food to alleviate chemotherapy-induced toxicity in cancer patients [Poster]. ASCO Annual Meeting. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11308534/
9. PDQ® Supportive and Palliative Care Editorial Board. (2024, September 20). Nutrition in cancer care (PDQ®): Health professional version. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/side-effects/appetite-loss/nutrition-hp-pdq
10. Yin, L., Vijaygopal, P., Menon, R., Vaught, L. A., Zhang, M., Zhang, L., Okunieff, P., & Vidyasagar, S. (2014). An amino acid mixture mitigates radiation-induced gastrointestinal toxicity. Health Physics, 106(6), 734–744. https://doi.org/10.1097/HP.0000000000000117
enterade® 2026. All rights reserved. This content is provided for informational and educational purposes only and does not constitute medical advice. Patients should consult their oncology care team before making any changes to their treatment plan or nutritional regimen.
